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Objectives.—To gauge consensus regarding a proposed definition for refractory migraine proposed by Refractory Head-
ache Special Interest Section, and where its use would be most appropriate.
Background.—Headache experts have long recognized that a subgroup of headache sufferers remains refractory to
treatment. Although different groups have proposed criteria to define refractory migraine, the definition remains controversial.
The Refractory Headache Special Interest Section of the American Headache Society developed a definition through a
consensus process, assisted by a literature review and initial membership survey.
Design.—A 12-item questionnaire was distributed at the American Headache Society meeting in 2007 during a platform
session and at the Refractory Headache Special Interest Section symposium. The same questionnaire was subsequently sent to
all American Headache Society members via e-mail. A total of 151 responses from AHS members form the basis of this report.
The survey instrument was designed using Survey Monkey. Frequencies and percentages of the survey were used to describe
survey responses.
Results.—American Headache Society members agreed that a definition for refractory migraine is needed (91%) that it
should be added to the International Classification of Headache Disorders-2 (86%), and that refractory forms of non-migraine
headache disorders should be defined (87%). Responders believed a refractory migraine definition would be of greatest value
in selecting patients for clinical drug trials. The current refractory migraine definition requires a diagnosis of migraine,
interference with function or quality of life despite modification of lifestyle factors, and adequate trials of acute and preventive
medicines with established efficacy. The proposed criteria for the refractory migraine definition require failing 2 preventive
medications to meet the threshold for failure. Although 42% of respondents agreed with the working definition of refractory
migraine, 43% favored increasing the number to 3 (50%) or 4 (26%) preventive treatment failures. When respondents were
asked if they felt that the proposed definition was appropriate to select patients for invasive procedures (patent foramen ovale
repair or stimulators) only 44% agreed.
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Conclusions.—There is a consensus for a need for a definition for refractory migraine and that it should be added to the
International Classification of Headache Disorder-2. There was also general agreement by the responders that refractory forms
of non-migraine headache disorders should be defined.
Key words: migraine, definition, refractory, survey
Abbreviations: AHS American Headache Society, Committee Definition Committee, ICHD-2 International Classification of
Headache Disorders-2, PFO patent foramen ovale, RH refractory headache, RHSIS Refractory Headache
Special Interest Section, RM refractory migraine
(Headache 2009;49:509-518)
Despite advances in headache therapies, some
patients do not satisfactorily respond to or cannot
tolerate current evidence-based treatments. This
group of patients is often said to have refractory
headache (RH). Although the concept of RH has a
long history, there have been few attempts to formal-
ize an operational definition.1 The International Clas-
sification of Diseases, Ninth Revision, Clinical
Modification (ICD-9-CM) includes “intractable” as a
modifier for migraine (including chronic migraine),
but is not formally defined.2 Goadsby et al were the
first to propose specific operational criteria for intrac-
table migraine and cluster headache based on an
international consensus panel.3
To further develop a definition, the Refractory
Headache Special Interest Section (RHSIS) of the
American Headache Society (AHS) attempted to
refine the definition of RH.4 In March of 2006, a
16-item self-administered Internet questionnaire was
sent to AHS members.5 Respondents were asked for
their opinion on various aspects of RH, including
duration, associated disability, response to medica-
tions, and whether RH should be considered as an
addition to the current International Classification of
Headache Disorders-2 (ICHD-2) classification.
Of respondents, 64% believed RH should occur
15 days per month and 55% believed it should be
associated with disability. A total of 79% of those
answering the survey believed the definition of RH
should include an inadequate response to multiple
abortive and preventative medications and 57.5%
believed it should be added to the ICHD-2 while
8.5% were opposed and 34% were unsure whether it
should be added.
The Definition Committee of RHSIS (Commit-
tee) proposed criteria for RM utilizing the first survey
results, a review of the literature, and collaborative
discussions (Table 1). As part of the validation
process, the Committee distributed a second survey
assessing agreement among AHS members with the
major components of the definition6 (Appendix). The
major components contained in the RM definition
included (1) meeting the criteria of ICHD-2 Migraine
or Chronic Migraine; (2) headaches that cause signifi-
cant interference with function or quality of life
despite modification of triggers, lifestyle factors; (3)
adequate trials of acute medication; and (4) adequate
trials of preventive medicines with established effi-
cacy. The proposed criteria also added modifiers for
RM with medication overuse and disability. We
present herein the results of that survey and our pro-
posal for revising the definition.
METHODS
A 12-item questionnaire was distributed at the
AHS meeting in 2007 during a platform session and at
the RHSIS symposium. The same questionnaire was
subsequently sent to all AHS members via e-mail. If
members had already completed the questionnaire at
the 2007 AHS meeting, they were asked not to com-
plete the survey again. At the AHS meeting, we col-
lected 90 completed surveys from AHS members. An
additional 91 surveys were obtained by e-mail, but
results were usable in only 61 subjects. A total of 151
responses from AHS members form the basis of this
report. The survey instrument was designed using
Survey Monkey.7 AHS surveys collected during the
AHS meeting were manually entered into the Survey
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Monkey database, while survey responses obtained
via e-mail were entered via automated direct data
entry. Frequencies and percentages of the survey
were used to describe survey responses. Not every
respondent answered all questions of the survey, and
thus, percentages for each question were based on the
total number of responses for that particular ques-
tion. Comparisons in survey responses by demo-
graphic characteristics were accomplished using
Fisher’s exact statistics.
RESULTS
Respondents.—Of the 1472 members of AHS,
151 (11%) participated in the survey. The demo-
graphic characteristics of the 151 respondents are
provided in Table 2 along with the collected charac-
teristics of all AHS members; the sample had a
mean age of 49 years and 66% were male. Of the
respondents, 70% were neurologists, 73% had been
in practice for at least 10 years, and 69% devoted at
least half their professional time to headache. Par-
ticipants were similar to the broader membership of
AHS.8
Need for and Purposes in Defining Refractory
Migraine.—There was overwhelming agreement with
a need for the definition of RM. As seen in Table 3,
91% of respondents either strongly agreed or agreed
there was a need for such a definition. This did not
significantly vary by specialty, years in practice, or
proportion of time devoted to the practice of
headache.
Table 1.—Proposed Criteria for Definition of Refractory Migraine and Refractory Chronic Migraine
Primary diagnosis A. ICHD-II Migraine or Chronic Migraine
B. Headaches cause significant interference with function or quality of life despite modification of triggers,
lifestyle factors, and adequate trials of acute and preventive medicines with established efficacy.





d. Calcium channel blockers
2. Failed adequate trials of abortive medicines from the following classes, unless contraindicated:
a. Both a triptan and DHE intranasal or injectable formulation
b. Either non-steroidal anti-inflammatory drugs (NSAIDs) or combination analgesics
Adequate trial Period of time during which an appropriate dose of medicine is administered, typically at least two (2)
months at optimal or maximum-tolerated dose, unless terminated early due to adverse effects.
Modifiers 1. With or without medication overuse, as defined by ICHD-II
2. With significant disability, as defined by MIDAS score 11











Neurology 68 (70%) 54%
Internal medicine/FP 7 (7%)



















Respondents were asked to select one or more
listed applications for the definition as being impor-
tant. As demonstrated in Table 4, those chosen
included selecting patients for clinical drug trials
(chosen by 85% of responders), for use in epidemio-
logic studies (77%), and in identifying those in need
of treatment by headache specialists (72%). In com-
parison to those in practice for less than 10 years,
those who were in practice for 10 years or more were
more likely to favor using the RM definition in clini-
cal trials of drug (89% vs 75%) and invasive devices
(75% vs 58%). Assessment of the importance of the
definition did not vary by specialty or percent of time
devoted to the practice of headache medicine.
Table 3.—Response to Survey Question: There is a Need for a Definition of Refractory Migraine†
Demographic characteristic Strongly agree/agree Neutral Disagree strongly P value‡
All responders (n = 147) 91% (134) 5% (8) 5% (5) n/a
Specialty
Neurology (n = 68) 93% (63) 3% (2) 4% (3) .5305
Other (n = 29) 86% (25) 7% (2) 7% (2)
Years in practice
<10 years (n = 39) 95% (37) 0% (0) 5% (2) .1145
10 years (n = 103) 90% (93) 8% (8) 2% (2)
Proportion of time devoted to patient care
<50% (n = 45) 93% (42) 7% (3) 0% (0) .4150
50% (n = 97) 91% (88) 5% (5) 4% (4)
†Responses expressed in percent based on total number of responders to survey question and to the demographic characteristic
being reported.
‡P value based on Fisher’s exact test.




need of treatment by
headache specialists
Identifying those











All responders (n = 151) 72% (108) 72% (109) 85% (128) 70% (106) 77% (116)
Specialty
Neurology (n = 68) 71% (48) 81% (55) 90% (61) 78% (53) 81% (55)
Other (n = 29) 79% (23) 79% (23) 86% (25) 66% (19) 76% (22)
P value‡ .4580 .9999 .7285 .2144 .5916
Years in practice
<10 years (n = 40) 68% (27) 70% (28) 75% (30) 58% (23) 73% (29)
10 years (n = 106) 74% (78) 74% (78) 89% (94) 75% (79) 78% (83)




<50% (n = 46) 61% (28) 63% (29) 78% (36) 70% (32) 74% (34)
50% (n = 100) 76% (76) 76% (76) 87% (87) 70% (70) 77% (77)
P value‡ .0768 .1165 .2219 .9999 .6817
†Responses expressed in percent based on total number of responders to survey question 2 and to the demographic characteristic
being reported.
‡P value based on Fisher’s exact test.
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Participants were then asked to choose and rank
the most important and second most important appli-
cation of the RM definition. Table 5 presents the dis-
tribution of applications ranked by responders by
order of importance for the definition of RH. When
asked which application of a RM definition was the
most important, respondents selected identifying
patients in need of treatment by headache specialists
(40%), identifying patients in need of inpatient treat-
ment (22%), use in clinical trials of drugs (18%) or
invasive devices (9%). When asked which application
was second most important, respondent selected
identifying those in need of specific treatment
modalities (33%) and selecting patients for clinical
drug trials (23%).
A total of 76% of responders indicated identify-
ing patients in need of treatment by a headache spe-
cialist or inpatient treatment as the first or second
most important applications for the definition. There
was no statistically significant difference in either the
first or second ranked applications by either specialty,
years in practice, or percent of practice devoted to
headache.
Revising the RM Definition.—In total, 42% of
respondents would not want to change the working
definition of RM for the application they ranked as
most important, while 43% wanted to make changes
for that application. The most frequently desired
change, reported by 41% of respondents, was to
increase the required number of failed preventative
medication classes. The criteria required failure in 2
classes. Of those who desired a change, 50% would
require 3 failed classes and 26% would require 4
failed classes.There was no statistically significant dif-
ference by either specialty, years in practice, or
percent of practice devoted to headache.
Twenty-four percent of responders would
modify the RM definition by increasing the number
of failed acute treatments. Of these, 45% wanted to
increase the number of failed acute treatments from
2 to 3, and 14% preferred to increase the number of
failed acute treatments to 4. Of the responders in
favor of changing the definition, 45% suggested
changes either by increasing the number of failed
preventives or abortive medications. Only 19%
thought that modifying the definition required
increasing both the number of abortive and preven-
tives agents.
For the application which responders ranked as
second most important, 61% would not change the
definition. Twenty-four percent of the responders
would increase the number of preventives necessary,
of which 75% suggested increasing the failed preven-
tives necessary from 2 to 3. Only 19% felt failing all 4
classes of preventives were necessary. Sixteen percent
would increase the number of abortives one needed
to fail, with 33% of these suggesting 3 abortive agents
be failed, and 25% favoring 4.
Responders were largely in agreement that 2
months on a preventive at optimal or maximum-
tolerated dose was an adequate trial. Sixty-eight
percent either strongly agreed or agreed with this
statement. Twenty-eight percent disagreed with this
period of treatment, and 4% were neutral. Of those
who thought 2 months was inadequate, most were in
favor of a 3-month trial (85%).












Identifying those in need of treatment by headache specialists 40% (47) 16% (19) 13% (15) 9% (11) 9% (10)
Identifying those in need of specific treatment modalities 22% (26) 33% (39) 13% (15) 9% (10) 3% (4)
Selecting patients for clinical drug trials 18% (21) 23% (27) 32% (38) 9% (10) 9% (10)
Selecting patients for invasive treatment trials 9% (11) 10% (12) 14% (16) 32% (37) 15% (17)
For use in epidemiologic studies 9% (10) 8% (9) 20% (24) 20% (23) 23% (27)
†Responses expressed in percent based on total number of responders to survey question 3.1 (n = 117).
‡No significant differences by specialty, years in practice, or time devoted to patient care.
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When asked whether the definition was adequate
for selecting patients for invasive trials such as PFO
repair or stimulators, only 44% agreed or strongly
agreed, while 34% were neutral, and 20% disagreed
or strongly disagreed. There was no significant differ-
ence by specialty, years in practice, or percent of prac-
tice devoted to headache.
There was consensus on whether the definition of
RM should be added to the ICHD-2. Eighty-six
percent agreed or strongly agreed with this statement.
There was agreement among responders that primary
headache types such as tension type (56%), cluster
(71%), and TACs (69%) were all candidates for the
designation “refractory.” There was also broad agree-
ment with headache disorders other than migraine
being designated as “refractory,” with 87% of respon-
dents agreeing or strongly agreeing with this state-
ment. Those spending greater than 50% of their time
on headache treatment or research were significantly
more in favor of this designation (92%) than those
spending less than 50% of their clinical time (74%).
There was no significant difference by specialty or
years in practice.
Finally, survey respondents were asked to
comment on the proposed RM definition. There were
a total of 111 comments from 68 respondents. Some
suggested that the RM definition could be utilized for
increased reimbursement in treatment of RM
patients, justifying the use of botulinum toxin injec-
tions, or for insurance coding. In terms of the RM
criteria, respondents commented that a failure of a
minimum of 2 triptans might be added in the acute
treatment criteria, while others suggested adding
failure of SNRI’s in the antidepressant class. Lastly,
other comments included a better definition of what
constitutes “failure” of a preventive.
DISCUSSION
The intent of the survey was to assess the views of
AHS members on the proposed definition of refrac-
tory migraine. Despite obtaining responses from 11%
of AHS members, our sample was broadly represen-
tative of AHS in terms of age and gender, specialty,
and duration in practice. There was widespread
agreement on the need for a definition of RM.
Most respondents felt there was a need for the defi-
nition for RM, that it should be added, to the ICHD-2,
and that criteria for refractory forms of other primary
headache disorders should be developed.
In the present survey, 84% favored adding a
formal definition for RM to the ICHD-2. This repre-
sents a 27% increase from the initial survey of AHS
members. This may reflect the visibility given to RH
via a proposed formal definition, recent literature,
and a RHSIS symposium at the AHS annual meeting.
The Committee’s primary impetus for generating
the definition was to facilitate the appropriate level of
care for refractory patients. Survey responders
ranked as optimizing patient treatment as the most
important need for a RM definition.There was agree-
ment between the Committee and those responding
to the survey that patient care was of paramount
importance.
We selected only AHS members because of their
interest in headache treatment and research. This
group may be biased in favor of the need for defining
and further study of RM. However, it is the authors’
belief that this group is most able to contribute to the
initiative at this stage because of their expertise and
experience.
Though the vast majority of respondents sup-
ported the development of a RM definition, most
favored one or more changes in the definition we
proposed. In our current survey, 41% reported were
in favor of modifying the criteria by increasing the
required number of failed preventative medication
classes to more than 2 out of 4 classes. There was
extensive discussion by the Committee in selecting
the appropriate number of preventives necessary to
meet the criteria of “failure.” While requiring failure
of 3 classes may create a higher threshold to obtain
higher intensity of treatment, it also would ensure
greater specificity and uniformity.Acknowledging the
criticism of the survey responders, the Committee
agreed to increase the number of preventives
required from 2 to 3.
Respondents to the survey indicated an interest
in a variety of applications for the RM definition. It
may be that the appropriate RM definition will vary
with the context and the objectives of the user. The
most suitable definition may be determined by the
risks and benefits of the application. To identify
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patients in need of referral to a specialist, a less
restrictive definition is desirable. If a patient fails 3
preventives and meets the other criteria, the patient
may be considered refractory to treatment at the
primary care level. A majority of the respondents felt
this definition was not stringent enough to identify
those who would qualify for trials using invasive
approaches. While the use of one definition that is
inclusive is less cumbersome, invasive trials carry a
higher risk of morbidity, and perhaps should be more
stringent. If the goal is to apply the definition in epi-
demiologic research, then it is crucial to have an
operational straightforward definition that can be
reliably applied on a broad scale.
CONCLUSION
There was broad agreement on a need for a RM
definition and its addition to the ICHD-2. Field
testing will be necessary to clarify whether our
current proposal distinguishes the group we intend to
define, bearing in mind the competing issues of speci-
ficity and sensitivity. Further modifications to the defi-
nition may be necessary. In the interim, discussion has
focused attention on the concept of RM. The
increased visibility of the applications of the defini-
tion will ultimately benefit RM patients.
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(The Refractory Headache Special Interest Section Survey)
Name: (Optional)____________________E-mail or Phone #: (Optional)____________________
Questions About You
Gender: Male Female Age:______years old
Your specialty: Neurology Internal Medicine/Family Practice Psychiatry/Psychology Nurse Practitioner/
Physician Assistant Dentist Other______
Years in Practice (Please do NOT count years in residency or training):
1-4 years 5-9 years 10-14 years 15-19 years 20 years
What proportion of your professional time is devoted to patient care, teaching and research related to headache?
<25% 25-49% 50-75% >75%
Are you an AHS member? Yes No
Refractory Migraine Questions
1. There is a need for a definition of Refractory Migraine?
Strongly agree Agree Neutral/Don’t know Disagree Strongly
2. Which of the following applications of a definition for Refractory Migraine are important or very important?
Check all that apply
a. For use in clinical practice to identify patients in need of treatment by headache specialists.
b. For use in clinical practice to identify patients in need of specific treatment modalities such as inpatient
treatment.
c. For use in clinical trials to identify patients potentially eligible for research using single or combination
drug treatments.
d. For use in clinical trials to identify patients potentially eligible for research of invasive treatments such as
PFO closure or occipital nerve stimulation.




Appendix. (Cont.) The RHSIS Survey
(The Refractory Headache Special Interest Section Survey)
3. Of the applications of the definition listed above list them by letter (ie, 1 a) here in their order of importance
to you. 1. ____________ 2 ____________ 3.____________ 4.____________ 5.____________ 6____________
4. How would you change the Refractory Migraine proposed definition for the purpose you ranked as most
important in question 3? Please check all that are applicable.
a. No changes
b. A higher number of preventatives needs to have been failed. (How many?____________)
c. A fewer number of preventatives needs to have been failed. (How many?____________)
d. A higher number of abortives needs to have been failed. (How many?____________)
e. A fewer number of abortives needs to have been failed. (How many?____________)
f. Eliminate the disability modifier.
g. Other, specify______________________________________________________________________________
5. How would you change the Refractory Migraine proposed definition for the purpose you ranked as second
most important above in question 3 (That is the one you ranked number 2?)
Please check all that are applicable.
a. No changes
b. A higher number of preventatives needs to have been failed. (How many?____________)
c. A fewer number of preventatives needs to have been failed. (How many?____________)
d. A higher number of abortives needs to have been failed. (How many?____________)
e. A fewer number of abortives needs to have been failed. (How many?____________)
f. Eliminate the disability modifier.
g. Other, specify______________________________________________________________________________
6. Two months, as stated in the current refractory migraine criteria, is sufficient to make a judgment as to
whether a medication is an effective migraine preventive or not.
Strongly agree Agree Neutral/Don’t know Disagree Strongly disagree
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Appendix. (Cont.) The RHSIS Survey
(The Refractory Headache Special Interest Section Survey)
7. How many months do you believe each individual headache preventative should be tried before reporting
it as a failed preventative medication, when it is at the appropriate dose for headache prevention and it is
tolerated by the patient?
2 months 3 months 4 months other (How many? ____________months)
8. Do you believe the criteria in the current definition are appropriate to select patients who may be
candidates for invasive procedures, such as PFO repair or stimulators?
Strongly agree Agree Neutral/Don’t know Disagree Strongly disagree
If no please explain:
9. A formal definition of Refractory Migraine should be added to the ICHD?
Strongly agree Agree Neutral/Don’t know Disagree Strongly disagree
10. Should headache disorders other than migraine be designated as refractory headache disorders?
Strongly agree Agree Neutral/Don’t know Disagree Disagree Strongly
11. If you agreed to question 10, which of the other headache disorders would you consider being modified by
the term “refractory”?
Tension-type headache Cluster headache
All trigeminal autonomic cephalgias Secondary headaches
Other, specify_________________________________ I would not consider other headache disorders
12. Other comments or suggestions:
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